Apofore
Cambridge
About Apofore
Apofore is developing novel therapeutics for Type 2 diabetes based on the naturally occurring protein, Apolipoprotein A-IV (apo A-IV). The company’s approach is based on the discovery by its scientific founder Patrick Tso, PhD, at the University of Cincinnati, of apo A-IV as an important regulator of insulin secretion and glucose homeostasis. Recombinant apo A-IV, the company’s lead therapeutic is in preclinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $500.0K
- Funding stage: Seed
- Last round: Seed (Aug 2011)
- Website: apofore.com
- Phone: 6094303922
Industries & Categories
Biotechnology, Diabetes, Therapeutics
Canonical: https://fsome.com/organization/apofore-219189 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.